Efficacy and safety of Rifaximin for the treatment of liver cirrhosis with covert hepatic encephalopathy
- Conditions
- iver cirrhosis
- Registration Number
- JPRN-UMIN000044657
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
1. Patients who are not in a clear state of consciousness 2. Patients with psychiatric disorders (depression, masked depression, schizophrenia, dementia, etc.) 3. Patients with malignant tumors including hepatocellular carcinoma 4. Patients with any of the following complications 1) Ascites requiring periodic drainage 2) Bleeding due to rupture of esophageal or gastric varices 3) Spontaneous bacterial peritonitis 4) Severe electrolyte abnormalities that may affect neuropsychiatric function 5. Patients with a history of hypersensitivity to rifaximin 6. Patients with the following serious complications 1) Patients with severe renal dysfunction or end-stage renal failure on dialysis 2) Patients with poorly controlled myocardial infarction, heart failure, angina pectoris, arrhythmia, etc. 7. New administration or change in dosage of synthetic disaccharides, carnitine, zinc, or laxatives between 4 weeks before and 12 weeks after administration of rifaximin 8. Pregnant women, lactating women, and patients who may or intend to become pregnant 9. Patients who have difficulty in oral intake 10. Other patients who are deemed by the physician to be inappropriate for the safe conduct of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The purpose of this study is to evaluate the efficacy of the Number connection test-A in improving liver cirrhosis with covert hepatic encephalopathy. Patients will be evaluated before, 4 weeks after, 8 weeks after, and 12 weeks after rifaximin administration.
- Secondary Outcome Measures
Name Time Method